Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 823-828

  Stayrook, Keith R ^a   Mckinzie, Jamie H ^a   Barbhaiya, Latta H ^a   Crowell, Pamela L ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Chemotherapy; MAP kinase; Monoterpene; Pancreatic neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PERILLYL ALCOHOL; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; PANCREAS CANCER; PRENYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CRICETINAE; MESOCRICETUS; MONOTERPENES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN ISOPRENYLATION; RAS PROTEINS; SIGNAL TRANSDUCTION; TERPENES;

EID: 0031841099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lowy DR, Willumsen BM: Function and regulation of Ras. Ann Rev Biochem 62: 851-891, 1993.
2. Buday L, Downward J: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73: 611-620, 1993.
3. Zhang X, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Elledge SJ, Marshall MS, Bruder JT, Rapp UR, Avruch J: Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364: 308-313, 1993.
4. Katz ME, McCormick F: Signal transduction from multiple Ras effectors. Curr Opin Genetics Dev 7: 75-79, 1997.
5. Howe LR, Leevers SJ, Gomez N, Nakielny S, Cohen P, Marshall CJ: Activation of the MAP kinase pathway by the protein kinase raf. Cell 71: 335-342, 1992.
6. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
7. Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem 65: 241-269, 1996.
8. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407, 1992.
9. Itoh T, Kaibuchi K, Masuda T, Yamamoto T, Matsuura Y, Maeda A, Shimizu K, Takai Y: The post-translational processing of ras p21 is critical for its stimulation of mitogen-activated protein kinase. J Biol Chem 26: 3025-3028, 1993.
10. Kikuchi A, Williams LT: The post-translational modification of Ras p21 is important for Raf-1 activation. J Biol Chem 269: 20054-20059, 1994.
11. Porfiri E, Evans T, Chardin P, Hancock JF: Prenylation of ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange. J Biol Chem 269: 22672-22677, 1994.
12. Tamanoi F: Inhibitors of Ras farnesyltransferases. Trends in Biochem. Sci 18: 349-353, 1993.
13. Sebti SM, Hamilton AD: Rational design of Ras prenyltransferase inhibtors as potent anticancer drugs. Biochem Soc Trans 24: 692-699, 1996.
14. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Luca BK, Levinson AD, Marsters JC: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260: 1937-1942, 1993.
15. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL,. Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1937, 1993.
16. Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MN: The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and periilyl alcohol. Cancer Lett 91: 169-175, 1995.
17. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN: Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochemical Pharmacol 47: 1405-1415, 1994.
18. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN: Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266: 17679-17685, 1991.
19. Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell PL: Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 96: 15-21, 1995.
20. Haag JD, Gould MN: Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34: 477-483, 1994.
21. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL: Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55: 979-983, 1995.
22. Reddy BS, Wang CX, Samaha H, Lubet R, Steele VE, Kelloff GJ, Rao CV: Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 57: 420-425, 1997.
23. Ripple G, Gould M, Stewart J, Tutsch K, Alberti D, Feierabend C, Simon K, Arzoomanian R, Pomplun M, Wilding G, Bailey H: Phase I trial of perillyl alcohol administered daily. Proc Am Assoc Cancer Res 38: 221, 1997.
24. Sumi S, Beauchamp RD, Townsend CM, Pour PM, Ishizuka J, Thompson JC: Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9: 657-661, 1994.
25. Hubchak S, Mangino MM, Reddy MK, Scarpelli DG: Characterization of differentiated Syrian golden hamster pancreatic duct cells maintained in extended monolayer culture. In Vitro Cell Devel Biol 26: 889-897, 1990.
26. Mangold KA, Hubchak S, Mangino MM, Laconi S, Scarpelli DG: In vitro carcinogenesis of hamster pancreatic duct cells: cellular and molecular alterations. Carcinogenesis 15: 1979-1984, 1994.
27. Gates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, Randall SK, Crowell PL, Crowell DN: Prenylation of oncogenic human PTPCAAX protein tyrosine phosphatases. Cancer Lett 110: 49-55, 1996.
28. Cox AD, Brtva TR, Lowe DG, Der CJ: R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells. Oncogene 9: 3281-3288, 1994.
29. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ: Activation of Racl, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 15: 6443-6453, 1995.
30. Lebowitz PF, Davide JP, Prcndergast GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15: 6613-6622, 1995.
31. Qiu RG, Chen J, Kirn D, McCormick F, Symons F: An essential role for Rac in Ras transformation. Nature 374: 457-459, 1995.
32. Olson MF, Ashworth A, Hall: An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269: 1270-1272, 1995.
33. James G, Goldstein JL, Brown MS: Resistance of K-RasBV12 proteins to farnesyl-transferase inhibitors in Ratl cells. Proc Natl Acad Sci. USA 93: 4454-4458, 1996.
34. Zhang FL, Kirschmeier P, Can D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR: Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase. J Biol Chem 272: 10232-10239, 1997.
35. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270: 6221-6226, 1995.
36. Lerner EC, Qian Y, Hamilton AD, Sebti SM: Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyl transferase inhibitor. J Biol Chem 270: 26770-26773, 1995.
37. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IAG: Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene 11: 1639-1647, 1995.